VJToday

FDA approves at-home starting dose of subcutaneous lecanemab for the treatment of Alzheimer’s disease

On July 13, 2026, the U.S. Food and Drug Administration (FDA) approved a new starting dosage regimen of the subcutaneous (SC) formulation of lecanemab for the treatment of adult patients with Alzheimer’s disease (AD). This approval provides patients with an at-home administration option, offering an alternative to the previously required intravenous (IV) infusion initiation.1

Alzheimer’s disease and lecanemab

Alzheimer’s disease is a progressive neurodegenerative disease affecting cognition and functional ability.1 A characteristic feature of AD is the accumulation of amyloid beta (Aβ) plaques in the brain, with soluble aggregated Aβ species believed to be the most neurotoxic and implicated in disease progression.1

Lecanemab is an IgG1 monoclonal antibody that selectively targets these soluble aggregated Aβ species and has been shown in preclinical animal models to reduce Aβ aggregation and prevent plaque formation.2 In July 2023, the FDA converted lecanemab from accelerated to traditional approval, marking the first confirmation of the clinical efficacy of a therapy targeting the underlying pathology of AD.3 Under the initial regimen, patients were required to begin treatment with IV lecanemab before transitioning to the subcutaneous (SC) formulation after 18 months.1 The approval of the SC starting-dose regimen enables at-home administration from treatment initiation, with the potential to improve treatment accessibility and reduce the burden associated with IV infusions.1

Watch our interview with Lars Lannfelt, MD, PhD, Uppsala University, Uppsala, Sweden, where he shares his expert insights into the development of lecanemab.

Pivotal data: BAN2401-G000-201 & CLARITY AD

The FDA approval of the SC lecanemab starting-dose regimen was supported by the established efficacy of IV lecanemab from the BAN2401-G000-201 (NCT01767311) and CLARITY AD (NCT03887455) trials, together with evidence demonstrating comparable results with SC administration.1, 2, 4

The Bayesian adaptive Phase IIb BAN2401-G000-201 trial was a randomized, double-blind, placebo-controlled study, evaluating the safety and efficacy of lecanemab in patients with early AD.2 A total of 854 patients received placebo (n=245) or lecanemab (n=609) across five dosing regimens. At 18 months, the 10 mg/kg biweekly regimen demonstrated significant reductions in brain amyloid burden (−0.306 SUVr units), supportive CSF biomarker changes, and favorable drug-placebo differences across clinical measures, including ADCOMS (27–30%), ADAS-Cog14 (47–56%), and CDR-SB (26–33%). The regimen was generally well tolerated, with amyloid-related imaging abnormalities with edema or effusion (ARIA-E) occurring in 9.9% of patients.2

These findings were confirmed in the Phase III CLARITY AD trial, a randomized, double-blind, placebo-controlled, 18-month study of 1,795 patients with early AD assigned 1:1 to lecanemab 10 mg/kg biweekly or placebo.4 At 18 months, lecanemab demonstrated a significantly smaller worsening in CDR-SB score: 1.21 with lecanemab and 1.66 with placebo (P<0.001). Lecanemab also showed reduced brain amyloid burden by 59.1 centiloids compared with placebo (95% CI: −62.6 to −55.6) in a substudy (n=698) and significant improvements across secondary endpoints, including ADAS-Cog14, ADCOMS, and ADCS-MCI-ADL. Infusion-related reactions occurred in 26.4% of participants, and ARIA-E occurred in 12.6%.4

Together, these trials provided the evidence base for the initial approval of IV lecanemab and now supports the approval of the SC formulation.2, 4

Clinical implications

The approval of the SC lecanemab starting-dose regimen represents continued progress in the evolving treatment landscape of AD. It is the first option that enables patients to initiate and continue lecanemab treatment at home, providing a more accessible alternative for individuals who may face challenges with clinic-based IV administration.1

Written by Clare Harris
Reviewed by Hannah Elkheir

References

  1. U.S. Food and Drug Administration. FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment. Available here. (Last accessed: 15/07/2026)
  2. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.
  3. U.S. Food and Drug Administration. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. Available here. (Last accessed: 16/07/2026)
  4. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388(1):9-21.